The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 6571-6596

  Kessler, Mirjana ^a   Fotopoulou, Christina ^b   Meyer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer stem cells (CSC); Cellular transformation; Fallopian tube; p53 signature; Serous ovarian cancer; STIC; Tumor microenvironment

Indexed keywords

CA 125 ANTIGEN; CAVEOLIN 1; CCAAT ENHANCER BINDING PROTEIN DELTA; CHEMOKINE RECEPTOR CCR1; CYCLIN B1; CYCLIN DEPENDENT KINASE 4; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NOTCH RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; POLO LIKE KINASE 1; PROTEIN P53; STAT3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR PAX8; UNINDEXED DRUG; UVOMORULIN; ZIBOTENTAN;

CANCER GROWTH; CANCER RESISTANCE; CANCER SCREENING; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHLAMYDIA TRACHOMATIS; DNA REPAIR; DRUG RESISTANCE; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HYSTEROSALPINGOGRAPHY; INFLAMMATION; LOW GRADE SEROUS OVARIAN CANCER; MALIGNANT TRANSFORMATION; METASTASIS; NEISSERIA GONORRHOEAE; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; OXIDATIVE STRESS; PARACRINE SIGNALING; REVIEW; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; SIGNAL TRANSDUCTION; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA; UTERINE TUBE MUCOSA; CANCER GRADING; CYSTADENOCARCINOMA; DNA FINGERPRINTING; FEMALE; GENETICS; MUTATION; OVARY TUMOR; PATHOLOGY; UTERINE TUBE TUMOR;

CYSTADENOCARCINOMA, SEROUS; DNA FINGERPRINTING; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS;

EID: 84875461548     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14046571     Document Type: Review

References (96)

1. Coleman, M.P.; Forman, D.; Bryant, H.; Butler, J.; Rachet, B.; Maringe, C.; Nur, U.; Tracey, E.; Coory, M.; Hatcher, J.; et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet 2011, 377, 127-138.
2. Baldwin, L.A.; Huang, B.; Miller, R.W.; Tucker, T.; Goodrich, S.T.; Podzielinski, I.; DeSimone, C.P.; Ueland, F.R.; van Nagell, J.R.; Seamon, L.G. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012, 120, 612-618.
3. Vaughan, S.; Coward, J.I.; Bast, R.C., Jr.; Berchuck, A.; Berek, J.S.; Brenton, J.D.; Coukos, G.; Crum, C.C.; Drapkin, R.; Etemadmoghadam, D.; et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11, 719-725.
4. Abe, A.; Minaguchi, T.; Ochi, H.; Onuki, M.; Okada, S.; Matsumoto, K.; Satoh, T.; Oki, A.; Yoshikawa, H. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum. Pathol. 2012, 44, 199-207.
5. Jones, S.; Wang, T.L.; Shih Ie, M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A., Jr.; Vogelstein, B.; et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330, 228-231.
6. Oliva, E.; Sarrio, D.; Brachtel, E.F.; Sanchez-Estevez, C.; Soslow, R.A.; Moreno-Bueno, G.; Palacios, J. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J. Pathol. 2006, 208, 708-713.
7. Hunter, S.M.; Gorringe, K.L.; Christie, M.; Rowley, S.M.; Bowtell, D.D.; Campbell, I.G. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin. Cancer Res. 2012, 18, 5267-5277.
8. Shih Ie, M.; Panuganti, P.K.; Kuo, K.T.; Mao, T.L.; Kuhn, E.; Jones, S.; Velculescu, V.E.; Kurman, R.J.; Wang, T.L. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am. J. Pathol. 2011, 178, 1442-1447.
9. Risch, H.A.; McLaughlin, J.R.; Cole, D.E.; Rosen, B.; Bradley, L.; Kwan, E.; Jack, E.; Vesprini, D.J.; Kuperstein, G.; Abrahamson, J.L.; et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001, 68, 700-710.
10. Tone, A.A.; Virtanen, C.; Shaw, P.; Brown, T.J. Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis. Clin. Cancer Res. 2012, 18, 4334-4344.
11. Cuatrecasas, M.; Villanueva, A.; Matias-Guiu, X.; Prat, J. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 1997, 79, 1581-1586.
12. Marquez, R.T.; Baggerly, K.A.; Patterson, A.P.; Liu, J.; Broaddus, R.; Frumovitz, M.; Atkinson, E.N.; Smith, D.I.; Hartmann, L.; Fishman, D.; et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 2005, 11, 6116-6126.
13. Cheung, H.W.; Cowley, G.S.; Weir, B.A.; Boehm, J.S.; Rusin, S.; Scott, J.A.; East, A.; Ali, L.D.; Lizotte, P.H.; Wong, T.C.; et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 12372-12377.
14. Mittag, J.; Winterhager, E.; Bauer, K.; Grummer, R. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007, 148, 719-725.
15. Bowen, N.J.; Logani, S.; Dickerson, E.B.; Kapa, L.B.; Akhtar, M.; Benigno, B.B.; McDonald, J.F. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol. Oncol. 2007, 104, 331-337.
16. Sundfeldt, K.; Piontkewitz, Y.; Ivarsson, K.; Nilsson, O.; Hellberg, P.; Brannstrom, M.; Janson, P.O.; Enerback, S.; Hedin, L. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer 1997, 74, 275-280.
17. Kabawat, S.E.; Bast, R.C., Jr.; Bhan, A.K.; Welch, W.R.; Knapp, R.C.; Colvin, R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 1983, 2, 275-285.
18. Li, J.; Abushahin, N.; Pang, S.; Xiang, L.; Chambers, S.K.; Fadare, O.; Kong, B.; Zheng, W. Tubal origin of "ovarian" low-grade serous carcinoma. Mod. Pathol. 2011, 24, 1488-1499.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
20. Powell, C.B.; Chen, L.M.; McLennan, J.; Crawford, B.; Zaloudek, C.; Rabban, J.T.; Moore, D.H.; Ziegler, J. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int. J. Gynecol. Cancer 2011, 21, 846-851.
21. Mingels, M.J.; Roelofsen, T.; van der Laak, J.A.; de Hullu, J.A.; van Ham, M.A.; Massuger, L.F.; Bulten, J.; Bol, M. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol. Oncol. 2012, 127, 88-93.
22. Callahan, M.J.; Crum, C.P.; Medeiros, F.; Kindelberger, D.W.; Elvin, J.A.; Garber, J.E.; Feltmate, C.M.; Berkowitz, R.S.; Muto, M.G. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 2007, 25, 3985-3990.
23. Olivier, R.I.; van Beurden, M.; Lubsen, M.A.; Rookus, M.A.; Mooij, T.M.; van de Vijver, M.J.; van't Veer, L.J. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br. J. Cancer 2004, 90, 1492-1497.
24. Finch, A.; Beiner, M.; Lubinski, J.; Lynch, H.T.; Moller, P.; Rosen, B.; Murphy, J.; Ghadirian, P.; Friedman, E.; Foulkes, W.D.; et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. J. Am. Med. Assoc. 2006, 296, 185-192.
25. Leeper, K.; Garcia, R.; Swisher, E.; Goff, B.; Greer, B.; Paley, P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 2002, 87, 52-56.
26. Kuhn, E.; Kurman, R.J.; Vang, R.; Sehdev, A.S.; Han, G.; Soslow, R.; Wang, T.L.; Shih, I.-M. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 2012, 226, 421-426.
27. Przybycin, C.G.; Kurman, R.J.; Ronnett, B.M.; Shih Ie, M.; Vang, R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am. J. Surg. Pathol. 2010, 34, 1407-1416.
28. Kindelberger, D.W.; Lee, Y.; Miron, A.; Hirsch, M.S.; Feltmate, C.; Medeiros, F.; Callahan, M.J.; Garner, E.O.; Gordon, R.W.; Birch, C.; et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 2007, 31, 161-169.
29. Carlson, J.W.; Miron, A.; Jarboe, E.A.; Parast, M.M.; Hirsch, M.S.; Lee, Y.; Muto, M.G.; Kindelberger, D.; Crum, C.P. Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 2008, 26, 4160-4165.
30. Pothuri, B.; Leitao, M.M.; Levine, D.A.; Viale, A.; Olshen, A.B.; Arroyo, C.; Bogomolniy, F.; Olvera, N.; Lin, O.; Soslow, R.A.; et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010, 5, e10358.
31. Gilbert, L.; Basso, O.; Sampalis, J.; Karp, I.; Martins, C.; Feng, J.; Piedimonte, S.; Quintal, L.; Ramanakumar, A.V.; Takefman, J.; et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project. Lancet Oncol. 2012, 13, 285-291.
32. Piek, J.M.; van Diest, P.J.; Zweemer, R.P.; Jansen, J.W.; Poort-Keesom, R.J.; Menko, F.H.; Gille, J.J.; Jongsma, A.P.; Pals, G.; Kenemans, P.; et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001, 195, 451-456.
33. Bernardini, M.Q.; Baba, T.; Lee, P.S.; Barnett, J.C.; Sfakianos, G.P.; Secord, A.A.; Murphy, S.K.; Iversen, E.; Marks, J.R.; Berchuck, A. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer 2010, 10, 237:1-237:10.
34. Jimenez, G.S.; Khan, S.H.; Stommel, J.M.; Wahl, G.M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999, 18, 7656-7665.
35. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007, 211, 26-35.
36. Xian, W.; Miron, A.; Roh, M.; Semmel, D.R.; Yassin, Y.; Garber, J.; Oliva, E.; Goodman, A.; Mehra, K.; Berkowitz, R.S.; et al. The Li-Fraumeni syndrome (LFS): A model for the initiation of p53 signatures in the distal Fallopian tube. J. Pathol. 2010, 220, 17-23.
37. Van Gent, D.C.; Hoeijmakers, J.H.; Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2001, 2, 196-206.
38. Richardson, C.; Stark, J.M.; Ommundsen, M.; Jasin, M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23, 546-553.
39. Arias-Lopez, C.; Lazaro-Trueba, I.; Kerr, P.; Lord, C.J.; Dexter, T.; Iravani, M.; Ashworth, A.; Silva, A. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 2006, 7, 219-224.
40. Ludwig, T.; Chapman, D.L.; Papaioannou, V.E.; Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997, 11, 1226-1241.
41. Hakem, R.; de la Pompa, J.L.; Sirard, C.; Mo, R.; Woo, M.; Hakem, A.; Wakeham, A.; Potter, J.; Reitmair, A.; Billia, F.; et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85, 1009-1023.
42. Bolton, K.L.; Chenevix-Trench, G.; Goh, C.; Sadetzki, S.; Ramus, S.J.; Karlan, B.Y.; Lambrechts, D.; Despierre, E.; Barrowdale, D.; McGuffog, L.; et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. J. Am. Med. Assoc. 2012, 307, 382-390.
43. Mukhopadhyay, A.; Plummer, E.R.; Elattar, A.; Soohoo, S.; Uzir, B.; Quinn, J.E.; McCluggage, W.G.; Maxwell, P.; Aneke, H.; Curtin, N.J.; et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012, 72, 5675-5682.
44. Norquist, B.; Wurz, K.A.; Pennil, C.C.; Garcia, R.; Gross, J.; Sakai, W.; Karlan, B.Y.; Taniguchi, T.; Swisher, E.M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29, 3008-3015.
45. George, S.H.; Greenaway, J.; Milea, A.; Clary, V.; Shaw, S.; Sharma, M.; Virtanen, C.; Shaw, P.A. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J. Pathol. 2011, 225, 106-117.
46. Tsilidis, K.K.; Allen, N.E.; Key, T.J.; Dossus, L.; Lukanova, A.; Bakken, K.; Lund, E.; Fournier, A.; Overvad, K.; Hansen, L.; et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br. J. Cancer 2011, 105, 1436-1442.
47. King, S.M.; Hilliard, T.S.; Wu, L.Y.; Jaffe, R.C.; Fazleabas, A.T.; Burdette, J.E. The impact of ovulation on fallopian tube epithelial cells: Evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr. Relat. Cancer 2011, 18, 627-642.
48. Lin, H.W.; Tu, Y.Y.; Lin, S.Y.; Su, W.J.; Lin, W.L.; Lin, W.Z.; Wu, S.C.; Lai, Y.L. Risk of ovarian cancer in women with pelvic inflammatory disease: A population-based study. Lancet Oncol. 2011, 12, 900-904.
49. Haggerty, C.L.; Gottlieb, S.L.; Taylor, B.D.; Low, N.; Xu, F.; Ness, R.B. Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 2010, 201, S134-S155.
50. Piura, B.; Sarov, I.; Sarov, B.; Kleinman, D.; Chaim, W.; Insler, V. Serum IgG and IgA antibodies specific for Chlamydia trachomatis in salpingitis patients as determined by the immunoperoxidase assay. Eur. J. Epidemiol. 1985, 1, 110-116.
51. Cooper, M.D.; Rapp, J.; Jeffery-Wiseman, C.; Barnes, R.C.; Stephens, D.S. Chlamydia trachomatis infection of human fallopian tube organ cultures. J. Gen. Microbiol. 1990, 136, 1109-1115.
52. Hvid, M.; Baczynska, A.; Deleuran, B.; Fedder, J.; Knudsen, H.J.; Christiansen, G.; Birkelund, S. Interleukin-1 is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection. Cell Microbiol. 2007, 9, 2795-2803.
53. Shaw, J.L.; Wills, G.S.; Lee, K.F.; Horner, P.J.; McClure, M.O.; Abrahams, V.M.; Wheelhouse, N.; Jabbour, H.N.; Critchley, H.O.; Entrican, G.; et al. Chlamydia trachomatis infection increases fallopian tube PROKR2 via TLR2 and NFkappaB activation resulting in a microenvironment predisposed to ectopic pregnancy. Am. J. Pathol. 2011, 178, 253-260.
54. Reddy, B.S.; Rastogi, S.; Das, B.; Salhan, S.; Verma, S.; Mittal, A. Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women-implication for T-cell responses. Clin. Exp. Immunol. 2004, 137, 552-558.
55. Kessler, M.; Zielecki, J.; Thieck, O.; Mollenkopf, H.J.; Fotopoulou, C.; Meyer, T.F. Chlamydia trachomatis disturbs epithelial tissue homeostasis in fallopian tubes via paracrine Wnt signaling. Am. J. Pathol. 2012, 180, 186-198.
56. Yu, H.; Schwarzer, K.; Forster, M.; Kniemeyer, O.; Forsbach-Birk, V.; Straube, E.; Rodel, J. Role of high-mobility group box 1 protein and poly(ADP-ribose) polymerase 1 degradation in Chlamydia trachomatis-induced cytopathicity. Infect. Immun. 2010, 78, 3288-3297.
57. Johnson, K.A.; Tan, M.; Sutterlin, C. Centrosome abnormalities during a Chlamydia trachomatis infection are caused by dysregulation of the normal duplication pathway. Cell Microbiol. 2009, 11, 1064-1073.
58. Sharma, M.; Machuy, N.; Bohme, L.; Karunakaran, K.; Maurer, A.P.; Meyer, T.F.; Rudel, T. HIF-1alpha is involved in mediating apoptosis resistance to Chlamydia trachomatis-infected cells. Cell Microbiol. 2011, 13, 1573-1385.
59. Ness, R.B.; Goodman, M.T.; Shen, C.; Brunham, R.C. Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J. Infect. Dis. 2003, 187, 1147-1152.
60. Ness, R.B.; Shen, C.; Bass, D.; Jackson, C.; Moysich, K.; Edwards, R.; Brunham, R.C. Chlamydia trachomatis serology in women with and without ovarian cancer. Infect. Dis. Obstet. Gynecol. 2008, 2008, 219672:1-219672:5.
61. Idahl, A.; Lundin, E.; Jurstrand, M.; Kumlin, U.; Elgh, F.; Ohlson, N.; Ottander, U. Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. Infect. Dis. Obstet. Gynecol. 2011, 2011, 824627:1-824627:10.
62. Collet, T.; Macnaughton, T.; Walsh, T.; Debattista, J.; Timms, P. Identification of novel markers for uncomplicated lower genital tract infections and upper genital tract pathology due to Chlamydia trachomatis. Int. J. Infect. Dis. 2011, 15, e257-e266.
63. Jazaeri, A.A.; Bryant, J.L.; Park, H.; Li, H.; Dahiya, N.; Stoler, M.H.; Ferriss, J.S.; Dutta, A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011, 13, 899-911.
64. Karst, A.M.; Levanon, K.; Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. USA 2011, 108, 7547-7552.
65. Kim, J.; Coffey, D.M.; Creighton, C.J.; Yu, Z.; Hawkins, S.M.; Matzuk, M.M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. USA 2012, 109, 3921-3926.
66. Sangha, N.; Wu, R.; Kuick, R.; Powers, S.; Mu, D.; Fiander, D.; Yuen, K.; Katabuchi, H.; Tashiro, H.; Fearon, E.R.; Cho, K.R. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 2008, 10, 1362-1372.
67. Ramus, S.J.; Vierkant, R.A.; Johnatty, S.E.; Pike, M.C.; van Den Berg, D.J.; Wu, A.H.; Pearce, C.L.; Menon, U.; Gentry-Maharaj, A.; Gayther, S.A.; et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int. J. Cancer 2008, 123, 380-388.
68. Baker, V.V.; Borst, M.P.; Dixon, D.; Hatch, K.D.; Shingleton, H.M.; Miller, D. c-myc amplification in ovarian cancer. Gynecol. Oncol. 1990, 38, 340-342.
69. Nakayama, N.; Nakayama, K.; Shamima, Y.; Ishikawa, M.; Katagiri, A.; Iida, K.; Miyazaki, K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116, 2621-2634.
70. Kurose, K.; Zhou, X.P.; Araki, T.; Cannistra, S.A.; Maher, E.R.; Eng, C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158, 2097-2106.
71. Zhang, N.; Wei, P.; Gong, A.; Chiu, W.T.; Lee, H.T.; Colman, H.; Huang, H.; Xue, J.; Liu, M.; Wang, Y.; et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20, 427-442.
72. Teh, M.T.; Wong, S.T.; Neill, G.W.; Ghali, L.R.; Philpott, M.P.; Quinn, A.G. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002, 62, 4773-4780.
73. Lok, G.T.; Chan, D.W.; Liu, V.W.; Hui, W.W.; Leung, T.H.; Yao, K.M.; Ngan, H.Y. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 2011, 6, e23790.
74. Gusarova, G.A.; Wang, I.C.; Major, M.L.; Kalinichenko, V.V.; Ackerson, T.; Petrovic, V.; Costa, R.H. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 2007, 117, 99-111.
75. Cheng, J.C.; Chang, H.M.; Leung, P.C. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene 2012, doi:10.1038/onc.2012.127.
76. Haslehurst, A.M.; Koti, M.; Dharsee, M.; Nuin, P.; Evans, K.; Geraci, J.; Childs, T.; Chen, J.; Li, J.; Weberpals, J.; et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012, 12, 91:1-91:10.
77. Rosano, L.; Cianfrocca, R.; Spinella, F.; Di Castro, V.; Nicotra, M.R.; Lucidi, A.; Ferrandina, G.; Natali, P.G.; Bagnato, A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res. 2011, 17, 2350-2360.
78. Lee, M.; Nam, E.J.; Kim, S.W.; Kim, S.; Kim, J.H.; Kim, Y.T. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Int. J. Gynecol. Cancer 2012, 22, 1489-1496.
79. Siu, M.K.; Wong, E.S.; Kong, D.S.; Chan, H.Y.; Jiang, L.; Wong, O.G.; Lam, E.W.; Chan, K.K.; Ngan, H.Y.; Le, X.F.; et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 2012, doi:10.1038/onc.2012.363.
80. Xu, C.X.; Xu, M.; Tan, L.; Yang, H.; Permuth-Wey, J.; Kruk, P.A.; Wenham, R.M.; Nicosia, S.V.; Lancaster, J.M.; Sellers, T.A.; et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J. Biol. Chem. 2012, 287, 34970-34978.
81. Jaks, V.; Barker, N.; Kasper, M.; van Es, J.H.; Snippert, H.J.; Clevers, H.; Toftgard, R. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat. Genet. 2008, 40, 1291-1299.
82. Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449, 1003-1007.
83. Barker, N.; Huch, M.; Kujala, P.; van de Wetering, M.; Snippert, H.J.; van Es, J.H.; Sato, T.; Stange, D.E.; Begthel, H.; van den Born, M.; et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6, 25-36.
84. Paik, D.Y.; Janzen, D.M.; Schafenacker, A.M.; Velasco, V.S.; Shung, M.S.; Cheng, D.; Huang, J.; Witte, O.N.; Memarzadeh, S. Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: A site for injury and serous cancer initiation. Stem Cells 2012, 30, 2487-2497.
85. Park, J.T.; Chen, X.; Trope, C.G.; Davidson, B.; Shih Ie, M.; Wang, T.L. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am. J. Pathol. 2010, 177, 1087-1094.
86. McAuliffe, S.M.; Morgan, S.L.; Wyant, G.A.; Tran, L.T.; Muto, K.W.; Chen, Y.S.; Chin, K.T.; Partridge, J.C.; Poole, B.B.; Cheng, K.H.; et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. USA 2012, 109, E2939-E2948.
87. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320.
88. Alvero, A.B.; Chen, R.; Fu, H.H.; Montagna, M.; Schwartz, P.E.; Rutherford, T.; Silasi, D.A.; Steffensen, K.D.; Waldstrom, M.; Visintin, I.; et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8, 158-166.
89. Silva, I.A.; Bai, S.; McLean, K.; Yang, K.; Griffith, K.; Thomas, D.; Ginestier, C.; Johnston, C.; Kueck, A.; Reynolds, R.K.; et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011, 71, 3991-4001.
90. Meirelles, K.; Benedict, L.A.; Dombkowski, D.; Pepin, D.; Preffer, F.I.; Teixeira, J.; Tanwar, P.S.; Young, R.H.; MacLaughlin, D.T.; Donahoe, P.K.; et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc. Natl. Acad. Sci. USA 2012, 109, 2358-2363.
91. Kryczek, I.; Liu, S.; Roh, M.; Vatan, L.; Szeliga, W.; Wei, S.; Banerjee, M.; Mao, Y.; Kotarski, J.; Wicha, M.S.; et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 2012, 130, 29-39.
92. Long, H.; Xie, R.; Xiang, T.; Zhao, Z.; Lin, S.; Liang, Z.; Chen, Z.; Zhu, B. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012, 30, 2309-2319.
93. Coffman, L.; Mooney, C.; Lim, J.; Bai, S.; Silva, I.; Gong, Y.; Yang, K.; Buckanovich, R.J. Endothelin receptor-A is required for the recruitment of anti-tumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol. Ther. 2012, 14, 184-192.
94. Acharyya, S.; Oskarsson, T.; Vanharanta, S.; Malladi, S.; Kim, J.; Morris, P.G.; Manova-Todorova, K.; Leversha, M.; Hogg, N.; Seshan, V.E.; et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150, 165-178.
95. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R.; Weinberg, R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449, 557-563.
96. Sato, T.; Vries, R.G.; Snippert, H.J.; van de Wetering, M.; Barker, N.; Stange, D.E.; van Es, J.H.; Abo, A.; Kujala, P.; Peters, P.J.; et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459, 262-265.